Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND.
- DOI
- 10.1007/s13555-026-01656-7
- Published
- 2026 Apr
- Container
- Dermatology and therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s13555-026-01656-7,
title = {Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND.},
author = {Blauvelt A and Hong HC and Katoh N and Langley RG and Laquer V and Lesiak A and Peris K and Seneschal J and Silvestre JF and Warren RB and Wollenberg A and Zirwas M and Bennike NH and Safavimanesh F and Tindberg AM and Reich K},
year = {2026},
journal = {Dermatology and therapy},
doi = {10.1007/s13555-026-01656-7},
url = {https://doi.org/10.1007/s13555-026-01656-7}
}RIS
TY - JOUR TI - Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND. AU - Blauvelt A AU - Hong HC AU - Katoh N AU - Langley RG AU - Laquer V AU - Lesiak A AU - Peris K AU - Seneschal J AU - Silvestre JF AU - Warren RB AU - Wollenberg A AU - Zirwas M AU - Bennike NH AU - Safavimanesh F AU - Tindberg AM AU - Reich K PY - 2026 JO - Dermatology and therapy DO - 10.1007/s13555-026-01656-7 UR - https://doi.org/10.1007/s13555-026-01656-7 ER -
APA
A, B., HC, H., N, K., RG, L., V, L., A, L., K, P., J, S., JF, S., RB, W., A, W., M, Z., NH, B., F, S., AM, T., & K, R. (2026). Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND.. Dermatology and therapy. https://doi.org/10.1007/s13555-026-01656-7
Source records
- pubmed · retrieved 2026-09-26T17:55:03.475Z